Survival Benefit With Lenvima/Keytruda for Advanced Clear Cell RCC Continues After 4 Years
June 5th 2023After a median follow-up of four years, the survival benefit, including progression-free survival persisted in patients with advanced clear cell renal cell carcinoma treated with Lenvima plus Keytruda compared with those treated with Sutent.
Read More
Sprycel Approved for CML Subset
November 10th 2017Sprycel (dasatinib), an oral medication that helps reduce the production of damaged white blood cells, has been approved by the Food and Drug Administration for the treatment of pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Read More
Tecentriq Approved as First-Line Treatment for Some Patients With Bladder Cancer
April 18th 2017The FDA has granted an accelerated approval to Tecentriq as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.
Read More
Ibrance Delays Progression of Breast Cancer in Phase 3 Trial
April 16th 2015The PALOMA-3 trial examining an Ibrance (palbociclib) regimen in HR-positive/HER2-negative breast cancer was halted after an independent panel determined it met the primary endpoint of improving progression-free survival.
Read More
Chemo Alone May Be Optimal for Some HER2-Positive Breast Cancer Patients
December 11th 2014Research presented at the 2014 San Antonio Breast Cancer Symposium shows that high levels of lymphocytes, white blood cells found in the immune system, could help identify women with HER2-positive breast cancer who could forego chemotherapy.
Read More